血友病:通过笔设备减少治疗负担
Chandrakala Shanmukaiah1, Parul Bhatt2, Kundan Mishra3
1Professor and Head, Department of Clinical Hematology, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra, India, Corresponding Author.
The Journal of the Association of Physicians of India
|November 24, 2025
概括
新的笔器件为血友病患者提供了一种更简单的方法来管理凝血因子,潜在地改善生活质量和治疗坚持. 这篇评论探讨了它们的好处和用户态度.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血友病是一种终身的凝血障碍,需要频繁的静脉凝血因子输液.
- 静脉注射带来了挑战,影响了患者的生活质量 (QoL) 和治疗坚持.
- 患者和护理人员希望更简单的皮下注射方法,类似于胰岛素笔.
研究的目的:
- 审查用于治疗血友病的新推出的笔器设备的优点.
- 探索患者和护理人员对这些皮下笔器件的态度.
主要方法:
- 这篇叙事综述综合了有关血友病治疗管理的当前文献.
- 它侧重于用于皮下注射的笔器件的好处和用户观点.
主要成果:
- 笔器件为静脉注射输液提供了一个潜在的不那么繁重的替代方案.
- 预计在皮下注射后会改善服药性和QoL.
- 患者和护理人员的接受对于成功的收养至关重要.
结论:
- 笔设备代表了血友病管理的重大进步.
- 它们解决了更容易自我管理的需要,潜在地提高了患者的坚持和QoL.
- 进一步的研究应该评估长期结果和患者满意度.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
443
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
443
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
427
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
427
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
538
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
538


